ArticleBioinformatics (Oxford, England)2019
DeepAMR for predicting co-occurrent resistance of Mycobacterium tuberculosis.
Article in Bioinformatics (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- ALPAR: automated learning pipeline for antimicrobial resistance.Bioinformatics (Oxford, England) · 2026Article
- Next-Generation Target Discovery in ESKAPE Pathogens: An AI-Driven Framework from Omics-Based to Systems-Level Modeling and Clinical Translation.Antibiotics (Basel, Switzerland) · 2026Review
- Artificial intelligence for antimicrobial resistance: advancing reproducibility, interpretability, and clinical deployment.Briefings in bioinformatics · 2026Review
- Advances in deep learning for antimicrobial research.Frontiers in microbiology · 2026Review
- Future Research Directions on Mycobacterium tuberculosis Proteins.Advances in experimental medicine and biology · 2026Review
- stackPredAMR-a stacked random forest approach improves AMR phenotype prediction for multiple species and antimicrobial agents.Bioinformatics advances · 2026Article
- Machine learning and statistical inference in microbial population genomics.Genome biology · 2025Review
- Predicting rifampicin resistance inERJ open research · 2025Article
- Enhanced diagnosis of multi-drug-resistant microbes using group association modeling and machine learning.Nature communications · 2025Article
- Feature selection and aggregation for antibiotic resistance GWAS inFrontiers in microbiology · 2025Article
- Applications and prospects of artificial intelligence in the auxiliary diagnosis of pediatric pulmonary tuberculosis.Frontiers in microbiology · 2025Review
- Integrating sequencing methods with machine learning for antimicrobial susceptibility testing in pediatric infections: current advances and future insights.Frontiers in microbiology · 2025Review
- AI-Driven Thoracic X-ray Diagnostics: Transformative Transfer Learning for Clinical Validation in Pulmonary Radiography.Journal of personalized medicine · 2024Article
- Article
- Review
- Tackling the Antimicrobial Resistance "Pandemic" with Machine Learning Tools: A Summary of Available Evidence.Microorganisms · 2024Review
- Prediction of pyrazinamide resistance inJAC-antimicrobial resistance · 2024Article
- Assessing computational predictions of antimicrobial resistance phenotypes from microbial genomes.Briefings in bioinformatics · 2024Article
- Deep learning for precise diagnosis and subtype triage of drug-resistant tuberculosis on chest computed tomography.MedComm · 2024Article
- TB-DROP: deep learning-based drug resistance prediction of Mycobacterium tuberculosis utilizing whole genome mutations.BMC genomics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
motivationResistance co-occurrence within first-line anti-tuberculosis (TB) drugs is a common phenomenon. Existing methods based on genetic data analysis of Mycobacterium tuberculosis (MTB) have been able to predict resistance of MTB to individual drugs, but have not considered the resistance co-occurrence and cannot capture latent structure of genomic data that corresponds to lineages.
resultsWe used a large cohort of TB patients from 16 countries across six continents where whole-genome sequences for each isolate and associated phenotype to anti-TB drugs were obtained using drug susceptibility testing recommended by the World Health Organization. We then proposed an end-to-end multi-task model with deep denoising auto-encoder (DeepAMR) for multiple drug classification and developed DeepAMR_cluster, a clustering variant based on DeepAMR, for learning clusters in latent space of the data. The results showed that DeepAMR outperformed baseline model and four machine learning models with mean AUROC from 94.4% to 98.7% for predicting resistance to four first-line drugs [i.e. isoniazid (INH), ethambutol (EMB), rifampicin (RIF), pyrazinamide (PZA)], multi-drug resistant TB (MDR-TB) and pan-susceptible TB (PANS-TB: MTB that is susceptible to all four first-line anti-TB drugs). In the case of INH, EMB, PZA and MDR-TB, DeepAMR achieved its best mean sensitivity of 94.3%, 91.5%, 87.3% and 96.3%, respectively. While in the case of RIF and PANS-TB, it generated 94.2% and 92.2% sensitivity, which were lower than baseline model by 0.7% and 1.9%, respectively. t-SNE visualization shows that DeepAMR_cluster captures lineage-related clusters in the latent space. AVAILABILITY AND IMPLEMENTATION: The details of source code are provided at http://www.robots.ox.ac.uk/∼davidc/code.php. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.